if I were a doctor and I had to choose between the two hyperkalemia drugs, I would not choose the one that caused higher blood pressure and edema. My kidney patients all have hypertension.
Short sellers will be unhappy soon...
Why do you think I put scare in quotes, the idea is that it will be an obvious point to make when selling against zs9: full of salt, hbp is aggravated by sodium, dude.
All good points. The sales force will easily be able to "scare" doctors into avoiding ZS009 with all that sodium, no question. So, even if ZS9 is approved without label, we will still win the battle for drs.!
Orwin reported that at BOA/ML presentation. Maybe not new info but impressive.
I was curious so I checked on the number of patients in the prevnar phase III data in 2011. It appears that a total of six studies covering 5667 patients are 50 to 93 were analyzed by the fda. This is based on a quick look at the fda report web address as follows:
If I'm reading this right, maybe the ACIP will be quicker to approve our Resolve based on a much larger number of patients tested so far.
I don't think it's a coincidence that the phase III RSV elderly trial was officially closed on May 1 (per Stan on CC) and the lease was entered on May 3rd.
There should be some discussion of how far they have progressed in concluding the big trial, and if they have begun unblinding the data.
Yes, everyone should find this on youtub and listen to it. zs-9 daily dose contains 2400 milligrams of salt and that suggests it will not be favored over Veltassa, which appears to lower bp. This doctor has read all the studies and is very fair about what is known and what is guesswork. Do yourself a favor and take 15 minutes if you are long RLYP. This is not just some wishful-thinking poster on a message board arguing long/short case.
You have been exposed as a liar. I went back and checked some of your other posts. On the surface they seem believable, but I found several more big lies you have told. In particular you stated that the current BOD of RLYP is composed of CEOs from other "failed biotechs". Biomarin (market cap 13bil) is a good exmaple of a non-failed biotech exec on the board. Many others expose your lies, too. Sleep well, d-bag.
Agreed, isn't this a revolutionary medical event? Relypsa has a safe, effective treatment to help millions of people live longer, better lives. Stay tuned!
As far as I know, Relypsa would not have to pay Centerview anything up front. So, the original negative rumor about it costing too much smells fishy!